GlassScriptPhysician profile
Aaron M Peterson
NPI 1457545303
$699,751.65
in general payments reported to CMS, 2019-2025
41 companies · $155K in 2025
The $155K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $57K · 2021: $53K · 2022: $120K · 2023: $140K · 2024: $138K · 2025: $155K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $380K · Travel and Lodging: $29K · Food and Beverage: $17K · Consulting Fee: $7,000 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $379,885.00 |
| Travel and Lodging | $28,705.63 |
| Food and Beverage | $17,089.53 |
| Consulting Fee | $7,000.00 |
| Education | $212.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $561,555.32 | 2021-2025 | |
| Allergan, INC. | $96,747.97 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20,844.96 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $5,717.31 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $1,969.73 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $1,682.34 | 2019-2025 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Lundbeck LLC | $1,013.56 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $1,004.93 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $935.56 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $890.82 | 2019-2025 | Trintellix |
| Bausch Health US, LLC | $886.80 | 2019-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $832.63 | 2021-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $811.79 | 2019-2022 | |
| Alkermes, INC. | $632.46 | 2019-2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $624.32 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $581.50 | 2019-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $419.40 | 2020-2025 | Xelstrym, Secuado |
| Teva Pharmaceuticals USA, INC. | $343.25 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $302.98 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $301.68 | 2019-2025 | Invega Sustenna, Spravato, Invega |
| Indivior INC. | $281.71 | 2023-2024 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $195.63 | 2024-2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $166.39 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $120.46 | 2019-2021 | |
| Adlon Therapeutics L.P. | $98.90 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $96.72 | 2022-2025 | Quviviq, Quviviq |
| Collegium Pharmaceutical, INC. | $81.51 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $80.63 | 2021-2025 | Loreev Xr |
| Owp Pharmaceuticals, INC. | $78.45 | 2019-2025 | Subvenite, Lamotrigine |
| Orexo US, INC. | $76.67 | 2019-2021 | |
| Shire North American Group INC | $64.04 | 2019 | |
| Validus Pharmaceuticals LLC | $55.58 | 2019 | |
| Arbor Pharmaceuticals, INC. | $47.17 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $38.07 | 2019-2025 | Relexxii |
| Rhodes Pharmaceuticals L.P. | $34.77 | 2019 | |
| Alfasigma USA, INC. | $32.74 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $30.63 | 2025 | Rejoyn |
| Tempus Ai, INC | $23.18 | 2025 | Tempus Pixel |
| Endo Pharmaceuticals INC. | $19.47 | 2019 | |
| Ibsa Pharma INC. | $14.84 | 2021 | |
| Currax Pharmaceuticals LLC | $14.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.